CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Morphosys AG - MOR CFD

18.87
1.87%
0.09
Low: 18.5
High: 19
Market Trading Hours* (UTC) Opens on Monday at 08:02

Mon - Fri: 08:02 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.024161 %
Charges from borrowed part ($-0.97)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.024161%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.020283 %
Charges from borrowed part ($-0.81)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.020283%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 20%
Stock exchange Germany
Commission on trade 0%

*Information provided by Capital.com

MorphoSys AG ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 19.23
Open* 19
1-Year Change* -31.56%
Day's Range* 18.5 - 19
52 wk Range 11.81-28.31
Average Volume (10 days) 108.88K
Average Volume (3 months) 7.20M
Market Cap 650.41M
P/E Ratio -100.00K
Shares Outstanding 34.16M
Revenue 249.61M
EPS -25.23
Dividend (Yield %) N/A
Beta 0.73
Next Earnings Date Mar 15, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 3, 2023 18.87 -0.42 -2.18% 19.29 19.29 18.26
Feb 2, 2023 19.23 0.56 3.00% 18.67 19.71 18.53
Feb 1, 2023 18.43 0.26 1.43% 18.17 18.73 18.14
Jan 31, 2023 17.96 0.25 1.41% 17.71 18.27 17.33
Jan 30, 2023 17.96 0.09 0.50% 17.87 18.22 17.75
Jan 27, 2023 18.06 0.18 1.01% 17.88 18.27 17.83
Jan 26, 2023 17.96 0.14 0.79% 17.82 18.18 17.70
Jan 25, 2023 17.73 0.67 3.93% 17.06 17.79 16.87
Jan 24, 2023 17.00 -0.45 -2.58% 17.45 17.69 16.88
Jan 23, 2023 17.47 0.23 1.33% 17.24 17.73 16.87
Jan 20, 2023 16.94 0.70 4.31% 16.24 17.23 16.05
Jan 19, 2023 16.30 -0.58 -3.44% 16.88 17.11 15.33
Jan 18, 2023 17.04 0.19 1.13% 16.85 17.27 16.57
Jan 17, 2023 16.97 0.69 4.24% 16.28 17.01 16.13
Jan 16, 2023 16.47 -0.07 -0.42% 16.54 16.82 16.17
Jan 13, 2023 16.42 1.14 7.46% 15.28 16.80 15.14
Jan 12, 2023 15.12 -0.38 -2.45% 15.50 15.68 14.89
Jan 11, 2023 15.06 0.14 0.94% 14.92 15.13 14.45
Jan 10, 2023 14.63 0.38 2.67% 14.25 14.94 14.14
Jan 9, 2023 14.36 0.46 3.31% 13.90 14.47 13.82

Morphosys AG Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 49.7435 66.7908 76.4425 71.7553 327.698 179.612
Revenue 49.7435 66.7908 76.4425 71.7553 327.698 179.612
Total Operating Expense 109.685 134.398 136.584 178.803 301.039 685.818
Selling/General/Admin. Expenses, Total 12.7561 15.7687 26.2302 55.7672 152.193 188.958
Research & Development 82.1921 103.315 83.988 103.861 120.489 219.072
Depreciation / Amortization 3.764 4.03 3.75 3.458 7.255 7.557
Interest Expense (Income) - Net Operating 0.208 0.359 -0.22 0.18 -18.237 -13.584
Unusual Expense (Income) 10.141 9.864 20.224 9.462 6.795 231.949
Other Operating Expenses, Total 0.62335 1.06219 0.81471 2.67494 13.4374 19.6719
Operating Income -59.941 -67.6077 -60.1411 -107.048 26.6592 -506.207
Interest Income (Expense), Net Non-Operating 0.132 -0.768 -0.237 1.354 -35.614 -81.632
Other, Net -0.05516 -0.41446 -0.0987 -0.8269 31.4468 -3.21234
Net Income Before Taxes -59.8642 -68.7901 -60.4768 -106.52 22.492 -591.051
Net Income After Taxes -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Net Income Before Extra. Items -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Net Income -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Income Available to Common Excl. Extra. Items -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Income Available to Common Incl. Extra. Items -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Dilution Adjustment 0
Diluted Net Income -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Diluted Weighted Average Shares 26.4434 28.9476 31.3389 31.6112 33.1679 33.4011
Diluted EPS Excluding Extraordinary Items -2.28347 -2.41217 -1.79241 -3.25879 2.95137 -15.4025
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0 0
Diluted Normalized EPS -2.0342 -2.19068 -1.20385 -3.04945 3.20838 -10.8879
Cost of Revenue, Total 1.79663 3.4002 19.1071 32.1947
Gross Profit 74.6459 68.3551 308.591 147.417
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 47.1896 38.234 41.2448 52.9435 41.4665
Revenue 47.1896 38.234 41.2448 52.9435 41.4665
Cost of Revenue, Total 5.04798 10.1363 7.48222 9.52819 7.89249
Gross Profit 42.1416 28.0977 33.7625 43.4153 33.574
Total Operating Expense 76.4968 109.175 122.582 376.565 111.856
Selling/General/Admin. Expenses, Total 38.4237 40.1544 51.347 50.7098 36.4825
Research & Development 32.3171 40.5068 62.6749 87.0124 65.048
Interest Expense (Income) - Net Operating -1.1 1.6 -1.7 -3.24
Unusual Expense (Income) -0.089 18.604 0.135 230.949 0.089
Other Operating Expenses, Total 1.89697 -1.8263 0.94256 1.60571 2.34434
Operating Income -29.3072 -70.9412 -81.3369 -323.621 -70.3899
Interest Income (Expense), Net Non-Operating 7.1 -7.7 4.2 -95.782 3.4
Other, Net -33.8928 113.038 -76.8684 4.06089 -55.6612
Net Income Before Taxes -56.0999 34.3967 -154.005 -415.342 -122.651
Net Income After Taxes -41.6082 20.8942 -112.772 -380.974 -122.651
Net Income Before Extra. Items -41.6082 20.8942 -112.772 -380.974 -122.651
Net Income -41.6082 20.8942 -112.772 -380.974 -122.651
Income Available to Common Excl. Extra. Items -41.6082 20.8942 -112.772 -380.974 -122.651
Income Available to Common Incl. Extra. Items -41.6082 20.8942 -112.772 -380.974 -122.651
Diluted Net Income -41.6082 20.8942 -112.772 -380.974 -122.651
Diluted Weighted Average Shares 32.7586 35.3712 34.1332 34.1487 34.1488
Diluted EPS Excluding Extraordinary Items -1.27015 0.59071 -3.30388 -11.1563 -3.59167
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -1.27191 1.20559 -3.30892 -6.76036 -3.58906
Depreciation / Amortization 1.7
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 308.056 340.681 388.905 303.693 1206.82 1132.97
Cash and Short Term Investments 145.074 164.26 358.964 272.504 1090.32 993.664
Cash 73.929 76.589 45.4598 44.314 109.795 123.248
Cash & Equivalents 1.25166 1.13313
Short Term Investments 69.8938 86.5382 313.504 228.19 980.522 870.416
Total Receivables, Net 149.682 163.833 20.7414 20.3408 89.8356 85.79
Accounts Receivable - Trade, Net 12.5967 11.2343 17.7329 15.0817 83.3543 75.911
Total Inventory 0.31037 0.30075 0.24516 0.28821 9.96266 20.7552
Prepaid Expenses 3.5 2.1 3.6 5.8 6.698 16.815
Other Current Assets, Total 9.48947 10.1868 5.35488 4.75963 10.0035 15.9454
Total Assets 463.6 415.398 538.764 496.439 1659.51 2556.25
Property/Plant/Equipment, Total - Net 4.18911 3.52635 3.53071 47.8131 50.7415 49.5921
Property/Plant/Equipment, Total - Gross 19.047 19.836 18.597 63.9362 68.4008 69.8613
Accumulated Depreciation, Total -14.858 -16.31 -15.066 -16.123 -17.659 -20.269
Goodwill, Net 7.3648 7.3648 3.67623 3.67623 1.61923 335.574
Intangibles, Net 60.5745 60.4821 43.6888 41.1221 69.3752 838.322
Note Receivable - Long Term 79.5212 0
Other Long Term Assets, Total 3.89409 3.34429 2.98172 1.13603 134.373 199.796
Total Current Liabilities 38.3019 47.701 45.9233 61.5579 200.459 284.538
Accounts Payable 8.636 4.818 7.399 11.012 47.818 73.787
Accrued Expenses 22.838 36.408 36.53 44.971 79.2 113.055
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 6.82795 6.47504 1.99429 3.04744 69.9627 94.0353
Total Liabilities 48.1399 56.7272 50.3911 101.738 1038.19 2311.38
Total Long Term Debt 0.21829 0.08779 0.07152 40.0416 314.724 322.13
Long Term Debt 0.21829 0.08779 0.07152 0 272.76 282.785
Deferred Income Tax 7.42184 7.81126 3.50723 0 5.05747 22.0654
Other Liabilities, Total 2.19788 1.12709 0.88908 0.13809 517.951 1682.64
Total Equity 415.46 358.671 488.373 394.702 621.322 244.876
Common Stock 29.1598 29.4208 31.8396 31.958 32.89 34.2319
Additional Paid-In Capital 428.361 438.558 619.908 628.177 748.979 833.321
Retained Earnings (Accumulated Deficit) -27.5487 -97.3751 -152.766 -255.78 -157.889 -672.349
Treasury Stock - Common -14.6482 -11.827 -10.3988 -8.35725 -4.86874 -3.08505
Unrealized Gain (Loss) 0.1361 -0.10548 0
Total Liabilities & Shareholders’ Equity 463.6 415.398 538.764 496.439 1659.51 2556.25
Total Common Shares Outstanding 28.7638 29.1011 31.5585 31.7322 32.7586 34.1488
Long Term Investments 95.9811 98.999 196.588 0
Other Equity, Total -0.21089 -1.29572 2.21142 52.7576
Current Port. of LT Debt/Capital Leases 2.52742 3.47855 3.66106
Capital Lease Obligations 40.0416 41.9638 39.3458
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 1257.38 1255.91 1294.76 1132.97 1013.44
Cash and Short Term Investments 1122.26 1095.34 1155.19 993.664 855.47
Cash 109.586 297.335 249.767 123.248 108.873
Short Term Investments 1012.67 798.01 905.426 870.416 746.597
Total Receivables, Net 104.173 108.192 82.0685 79.227 80.0492
Accounts Receivable - Trade, Net 101.298 97.1665 77.044 75.911 74.0944
Total Inventory 13.4 14.5171 13.2692 20.7552 20.89
Prepaid Expenses 17.5465 37.8531 44.2278 39.3234 57.0263
Total Assets 1649.91 1577.41 2883.94 2556.25 2457.36
Property/Plant/Equipment, Total - Net 49.9224 49.4239 51.9162 49.5921 48.6483
Goodwill, Net 1.61923 1.61923 570.959 335.574 342.343
Intangibles, Net 69.0447 79.0253 787.906 838.322 853.209
Long Term Investments 125.713 55.3782 0 0
Other Long Term Assets, Total 146.23 136.061 178.404 199.796 199.721
Total Current Liabilities 202.263 204.554 259.123 284.538 238.959
Payable/Accrued 124.297 134.663 168.399 188.077 145.55
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4.02894 3.68179 4.09169 3.66106 5.31028
Other Current Liabilities, Total 73.9369 66.2085 86.6328 92.8001 88.0983
Total Liabilities 1070.25 976.007 2286.69 2311.38 2315.62
Total Long Term Debt 316.63 318.27 320.184 322.13 322.835
Long Term Debt 275.193 277.677 280.218 282.785 284.218
Capital Lease Obligations 41.4369 40.5935 39.9657 39.3458 38.6175
Deferred Income Tax 2.32821 5.05747 23.8584 22.0654 22.5267
Other Liabilities, Total 549.032 448.126 1683.53 1682.64 1731.3
Total Equity 579.653 601.407 597.25 244.876 141.739
Common Stock 32.89 32.8925 34.2319 34.2319 34.2319
Additional Paid-In Capital 749.846 749.284 832.584 833.321 833.376
Retained Earnings (Accumulated Deficit) -199.497 -178.603 -291.375 -672.349 -795
Treasury Stock - Common -4.86874 -3.78304 -3.37201 -3.08505 -3.08505
Other Equity, Total 1.2836 1.61683 25.1808 52.7576 72.2164
Total Liabilities & Shareholders’ Equity 1649.91 1577.41 2883.94 2556.25 2457.36
Total Common Shares Outstanding 32.7586 32.7905 34.141 34.1488 34.1488
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -60.3828 -69.8265 -56.1721 -103.014 97.8906 -514.46
Cash From Operating Activities -46.6157 -38.4459 -32.7813 -81.0702 34.5197 -481.445
Cash From Operating Activities 3.76381 4.02895 3.75026 6.24516 8.32956 10.091
Non-Cash Items -4.4191 -3.29514 24.182 -2.07177 -83.4769 200.528
Cash Taxes Paid 0.54038 1.86198 0.03384 0.06256 0.30397 64.6096
Cash Interest Paid 0.00182 0 0.13427 1.01132 1.43149 4.74485
Changes in Working Capital 14.4224 30.6468 -4.54142 17.7704 11.7764 -177.604
Cash From Investing Activities -80.786 32.9325 -177.751 79.4841 -879.623 -831.01
Capital Expenditures -2.91349 -13.1489 -2.46532 -3.66564 -49.3365 -26.1562
Other Investing Cash Flow Items, Total -77.8726 46.0813 -175.285 83.1497 -830.286 -804.854
Cash From Financing Activities 110.403 8.17382 179.462 0.35324 907.186 1322.92
Financing Cash Flow Items -2.78047 -0.01553 -15.1726 -1.01132 508.655 1241.08
Issuance (Retirement) of Stock, Net 113.19 0 193.614 0 80.5985 84.73
Issuance (Retirement) of Debt, Net -0.00671 8.18935 1.02085 1.36456 317.933 -2.88511
Foreign Exchange Effects 0 -0.05946 0.08712 3.39766 2.98531
Net Change in Cash -16.999 2.66047 -31.1293 -1.14579 65.4806 13.4536
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -41.6082 -20.714 -133.486 -514.46 -122.651
Cash From Operating Activities -42.2207 -131.585 -323.96 -481.445 -143.812
Cash From Operating Activities 2.31626 4.65405 7.3535 10.091 2.57174
Non-Cash Items 16.223 -79.0437 -68.6942 200.528 36.1088
Cash Taxes Paid 0.07992 0.08336 1.31085 64.6096 0.07782
Cash Interest Paid 0.53635 2.21944 2.91855 4.74485 0.42117
Changes in Working Capital -19.1517 -36.4816 -129.134 -177.604 -59.8415
Cash From Investing Activities 33.1924 292.728 -850.081 -831.01 115.187
Capital Expenditures -0.82796 -12.4208 -17.0882 -26.1562 -1.1706
Other Investing Cash Flow Items, Total 34.0204 305.149 -832.993 -804.854 116.358
Cash From Financing Activities 11.0258 27.857 1317 1322.92 13.7736
Financing Cash Flow Items 11.8149 29.2795 1234.36 1241.08 14.5762
Issuance (Retirement) of Stock, Net 0 0 84.7314 84.73
Issuance (Retirement) of Debt, Net -0.78905 -1.42251 -2.09185 -2.88511 -0.80261
Foreign Exchange Effects -2.20631 -1.45931 -2.98555 2.98531 0.47603
Net Change in Cash -0.20874 187.54 139.973 13.4536 -14.3749
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 5.743 1965924 661108 2023-01-12 LOW
Armistice Capital LLC Hedge Fund 5.1648 1768000 732000 2023-01-10 HIGH
Goldman Sachs Asset Management, L.P. Investment Advisor 4.7869 1638637 -39276 2023-01-18 LOW
T. Rowe Price International Ltd Investment Advisor/Hedge Fund 3.942 1349436 -250322 2022-02-16 MED
RP Management, LLC Private Equity 3.9073 1337552 1337552 2021-07-29 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 3.6317 1243209 376568 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.2165 1101057 -84879 2022-10-06 LOW
Adage Capital Management, L.P. Hedge Fund 3.2134 1100000 1100000 2022-12-02 LOW
Artisan Partners Limited Partnership Investment Advisor 2.9531 1010913 10045 2021-09-20 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.819 965001 11213 2022-12-31 LOW
Baillie Gifford & Co. Investment Advisor 2.4401 835292 -1213122 2022-12-16 LOW
Morgan Stanley Corporation 1.5309 524062 524062 2022-11-21 LOW
Invesco Advisers, Inc. Investment Advisor 1.3857 474360 0 2022-12-31 LOW
Bank of America Corp Corporation 1.2942 443038 128097 2022-12-22 MED
AMG Fondsverwaltung AG Investment Advisor 1.2112 414617 67321 2022-04-30 LOW
Eleva Capital SAS Investment Advisor 1.1824 404760 404760 2022-10-31 HIGH
Lupus alpha Asset Management AG Investment Advisor/Hedge Fund 1.1072 379000 -52000 2022-10-31 MED
Mirova Investment Advisor 1.0159 347778 -945 2022-11-30 LOW
Candriam Luxembourg S.A. Investment Advisor 0.9603 328727 0 2022-12-31 HIGH
Macquarie Investment Management Investment Advisor 0.8764 300000 0 2022-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Morphosys Company profile

About MorphoSys AG

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, MorphoSys AG revenues decreased 45% to EUR179.6M. Net loss totaled EUR514.5M vs. income of EUR97.9M. Revenues reflect USA and Canada segment decrease of 51% to EUR156.3M. Net loss reflects Impairment - Goodwill increase from EUR2.1M to EUR230.7M (expense), Other R&D increase of 80% to EUR153.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR3.01 to -EUR15.40.

Equity composition

12/2008, 3-for-1 stock split.

Industry: Biotechnology & Medical Research (NEC)

Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE

Income Statement

  • Annual
  • Quarterly

News

S&P 500, FTSE 100

S&P 500 & DAX 40 Forecast for the Week Ahead

S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance

16:30, 3 February 2023
Global Currencies.

FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis

USD, GBP/USD, USD/JPY forecasts for the week ahead.

15:56, 3 February 2023
Governor of the Bank of England Andrew Bailey addresses the media during the Monetary Policy Report press conference at the Bank of England, in London, on February 2, 2023

GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes

Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.

15:37, 2 February 2023
Gold bars

Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data

Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing

11:48, 2 February 2023

British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision

Bank of England remains a dovish hiker. GBP at risk of another dovish twist

15:13, 1 February 2023

People also watch

Natural Gas

2.41 Price
-2.390% 1D Chg, %
Long position overnight fee -0.1138%
Short position overnight fee 0.0796%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

23,412.15 Price
-0.150% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

73.41 Price
-3.570% 1D Chg, %
Long position overnight fee -0.0223%
Short position overnight fee 0.0065%
Overnight fee time 22:00 (UTC)
Spread 0.03

XRP/USD

0.41 Price
-0.880% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00327

Market analysis

Financial data on the monitor

Projected interest rates in 5 years: Can Fed stomach pushing rates beyond 10%?

17:44, 3 February 2023
Pi Network logo displayed on a smartphone

Pi Network price prediction: What is PI?

14:15, 3 February 2023
The Solana logo, featuring the letter S within a blue neon circle, on a black background

Solana price prediction: Can SOL rebound?

12:40, 3 February 2023

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading